Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

NCT02676778 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT02676778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02676778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 28, 2016
Completion date
April 26, 2019
Enrollment
45 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma, peripheral t-cell lymphoma